The Role of Somatostatin in the Hemodynamics of the Hepatic Circulation in Patients Undergoing Liver Resection

• Status: Unknown status
• Trial end date: 2020-07-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the present clinical trial is to study the effect of somatostatin in the regulation of velocity and blood flow of the hepatic circulation in patients undergoing liver resection. The patients will be randomized in two groups: the study group will receive somatostatin and the control group will receive the placebo. In both groups, patients will undergo hepatectomy and directly postoperatively they will receive either somatostatin or placebo, depending on their randomization. The primary endpoint will be the increase or decrease of the velocity and the flow of the hepatic circulation estimated by ultrasonography compared to the same parameters when measured preoperatively.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Laikο General Hospital, Athens
• Treatments: Somatostatin

Criteria

Inclusion Criteria:

• Patients undergoing hepatectomy for any reason including primary malignant liver tumors (hepatocellular carcinomas, cholangiocellular carcinomas, etc), metastatic liver disease and symptomatic benign liver lesions (liver adenomas, focal nodular hyperplasia, hemangiomas, etc).

• Adult patients (≥18 years old)

• Patients whose indication for hepatectomy will be decided by a multidisciplinary team meeting.

• Patients who eill agree to sign an informed consent

Exclusion Criteria:

• Patients who do not meet the inclusion criteria and those

• Patients undergoing synchronous hepatectomy-colectomy.